Views & Analysis Neurotechnology for tailored patient care Advanced implantable medical devices could treat hundreds of chronic conditions in the future.
News FDA knocks back Zealand's dasiglucagon once again Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.
